With the development of weight loss injections, the battle against obesity found a new meaning. The current treatments work by mimicking the effects of glucagon-like peptide-1 (GLP-1) which normally regulates appetite and food intake. Recent studies has shown how these injections were able to improve cardiometabolic parameters among the obese populations and overnight these injections became the blockbuster drugs. However, not all obese individuals prefer to use weight loss injections due to their side-effect profile or simply due to being trypanophobia. Nevertheless, this is about to change with amycretin, a new weight loss drug that has shown some promising early results which are even more promising than the current available weight loss injection. More interestingly, it is a pill! Based on the latest phase 1 trial results, the amycretin has shown a 13% reduction in body weight over the 3 months compared to only 6% reduction seen with previous weight loss injections. Nonetheless, experts warn that the data is still very premature and would require peer-reviewed published clinical trial data to substantiate these reported findings.

References:

1. Ruseva A, et al. Obes Sci Pract 2024;10(1):e737. 

2. Cross, P. I., PhD. (2024, March 19). New weight loss pill amycretin more effective than semaglutide in early trial. Available at: https://www.medicalnewstoday.com/articles/new-weight-loss-pill-amycretin-more-effective-than-semaglutide-in-early-trial